Postoperative Pain Management on Uvulopalatopharyngoplasty Patients

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized controlled study, aimed to investigate the effects of dinalbuphine sebacate (DS) on patients having uvulopalatopharyngoplasty (UPPP). DS is a prodrug of nalbuphine, a mixed agonist-antagonist opioid. The mean absorption time for the complete release of DS into systemic circulation is approximately 145 h, which could theoretically provide extended analgesic effects for up to 6 days. Patients diagnosed with obstructive sleep apnea are generally associated with higher risks towards opioid side effects, especially respiratory depression. Post-UPPP pain managing should be cautiously arranged and executed. We hypothesize that the combination of our routine practice and DS will improve the outcomes after Uppp.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Li-Jen Hsin

Criteria

Inclusion Criteria:

• aged between 20 and 65.

• diagnosed with obstructive sleep apnea.

• arranged to undergo uvulopalatopharyngoplasty.

• classified as ASA I, II, or III.

Exclusion Criteria:

• can not comply with study protocol.

• BMI > 34 kg/m2.

• history of chronic pain.

• history of narcotics or alcohol abuse.

• allergic to NSAID.

• diagnosed as diabetes mellitus with poor glycemic control.

• diagnosed with severe cardiovascular or respiratory diseases.

• judged as an unsuitable subject by investigators.